Get Cash Back and $0 Commissions + The Power of TradeStation
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
Globe Newswire 25-Feb-2025 7:00 AM
– Company presentation scheduled on Tuesday, March 4th at 9:10am ET –
– EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses from Phase 2 VERONA clinical trial in DME –
WATERTOWN, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., EyePoint's President and CEO, will present an update on enrollment for its ongoing Phase 3 pivotal program of DURAVYU in wet age-related macular degeneration (wet AMD) and additional subgroup analyses for the Phase 2 VERONA trial for DURAVYU in diabetic macular edema (DME) at the TD Cowen 45th Annual Health Care Conference.
Cowen 45th Annual Health Care Conference Forum: Corporate Presentation Date: Tuesday, March 4, 2025 Time: 9:10 a.m. ET
A live webcast and subsequent archived replay of each presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint
EyePoint (NASDAQ:EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
